Loading data for ONC — first visit, this takes a few seconds.

アラート

BeOne Medicines AG (ONC)

NasdaqGS: ONC · リアルタイム株価 · USD

371.98

-2.49 (-0.66%)

終値時点： Aug 25, 2026, 8:00 PM

375.00

-0.36%

時間外: 7:30 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

-0.66% (1D)

データがありません

買気配	346.74
時価総額	42.58B
売上高（TTM）	6.13B
純利益（TTM）	655.71M
	0.50
	5.58
	67.45
	36.6
PBR（TTM）	8.22
PSR（TTM）	6.95
決算発表日	Nov 5, 2026

売気配	360.25
出来高	349,775
平均出来高（20日）	356,920
始値	369.77
前日終値	374.47
当日レンジ	365.14 - 372.73
52週レンジ	253.95 - 385.22
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

ONCについて

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVA...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Feb 3, 2016

従業員数 12,000

上場取引所 NasdaqGS

ティッカー ONC

ウェブサイト https://beonemedicines.com

企業情報の全文

業績

2025年のBeOne Medicinesの売上高は5.34Bで、前年の3.81Bから40.23%の増加でした。利益は286.93Mで、-144.5%の減少でした。

財務諸表

決算サプライズ

BeOne MedicinesはAug 5, 2026に四半期決算を発表しました：

売上高は $1.71B で、予想を下回りました $0, うち 29.63% の前年比増加にあたります.
EPSは 2.05 で、予想を上回りました 0.42, うち 144.05% の前年比増加にあたります.

次回決算発表

BeOne Medicines AGの決算発表予定日は Nov 5, 2026, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1週間前 · Insider Monkey

Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?

Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the Augus...

1週間前 · GuruFocus.com

BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...

BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.

2週間前 · Simply Wall St.

Is BeOne Medicines (ONC) Undervalued Following Its Earnings Beat And Raised Outlook?

BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings surpassing analyst expectations and the company lifting its full year 2026 out...

2週間前 · MarketBeat

BeOne Medicines Q2 Earnings Call Highlights

BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued ...

2週間前 · Zacks

BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some o...

2ページ中1ページ

BeOne Medicines AG (ONC)